Elevation of maternal serum human chorionic gonadotropin (hcg) is not a marker of increased trophoblast mitogenic activity

A. Ghidini, C. Y. Spong, C. Lmtckf, G. A. Dildy, J. Greenhagen, M. V. Varner, M. Ossandon, J. C. Pezzulla

Research output: Contribution to journalArticle

Abstract

OBJECTIVE: Second trimester elevation of maternal serum (MS) hCG has been associated with untoward pregnancy outcome, yet its pathogenesis is unknown. We have hypothesized that elevated hCG is due to increased trophoblast proliferation. To test this hypothesis we have measured amniotic fluid (AF) levels of hepatocyte growth factor (HGF), a potent mitogenic and angiogenic factor released by and active on second trimester syncytiotrophoblast. STUDY DESIGN: AF levels of HGF {Quantikine, R&D Systems) in women with elevated MS hCG at the triple screening who underwent second trimester amniocentesis (n=20) were compared with those of women who had normal MS hCG levels at triple screening and underwent amniocentesis for standard genetic indications (n = 40). Included were singleton gestations with no evidence of fetal structural or chromosomal anomalies. Statistical analysis included x2. one-way ANOVA, multivariate analysis and correlation after log-transformation. RESULTS: Mean ±standard deviation maternal age {29±8 vs 36±7 years, p<0.05) and gestational age at sampling f 19±4 weeks vs 17±2 weeks, p<0.05) were different between women with high MS hCG vs those of women with normal or unknown hCG levels. AF HGF levels were not significantly different between the two groups (95,165± 68,825 vs 71,507±56,414, respectively, p=0.62). The lack of significance persisted after correcting for maternal age, gestational age at sampling, and year of sampling. CONCLUSIONS: Elevation of MS hCG is not associated with increased production and release of the mitogen HGF into the AF.

Original languageEnglish (US)
Pages (from-to)S158
JournalActa Diabetologica Latina
Volume176
Issue number1 PART II
StatePublished - Dec 1 1997
Externally publishedYes

Fingerprint

Trophoblasts
Chorionic Gonadotropin
Hepatocyte Growth Factor
Amniotic Fluid
Mothers
Second Pregnancy Trimester
Serum
Amniocentesis
Maternal Age
Gestational Age
Angiogenesis Inducing Agents
Pregnancy Outcome
Mitogens
Analysis of Variance
Multivariate Analysis
Pregnancy

ASJC Scopus subject areas

  • Internal Medicine
  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

Ghidini, A., Spong, C. Y., Lmtckf, C., Dildy, G. A., Greenhagen, J., Varner, M. V., ... Pezzulla, J. C. (1997). Elevation of maternal serum human chorionic gonadotropin (hcg) is not a marker of increased trophoblast mitogenic activity. Acta Diabetologica Latina, 176(1 PART II), S158.

Elevation of maternal serum human chorionic gonadotropin (hcg) is not a marker of increased trophoblast mitogenic activity. / Ghidini, A.; Spong, C. Y.; Lmtckf, C.; Dildy, G. A.; Greenhagen, J.; Varner, M. V.; Ossandon, M.; Pezzulla, J. C.

In: Acta Diabetologica Latina, Vol. 176, No. 1 PART II, 01.12.1997, p. S158.

Research output: Contribution to journalArticle

Ghidini, A, Spong, CY, Lmtckf, C, Dildy, GA, Greenhagen, J, Varner, MV, Ossandon, M & Pezzulla, JC 1997, 'Elevation of maternal serum human chorionic gonadotropin (hcg) is not a marker of increased trophoblast mitogenic activity', Acta Diabetologica Latina, vol. 176, no. 1 PART II, pp. S158.
Ghidini, A. ; Spong, C. Y. ; Lmtckf, C. ; Dildy, G. A. ; Greenhagen, J. ; Varner, M. V. ; Ossandon, M. ; Pezzulla, J. C. / Elevation of maternal serum human chorionic gonadotropin (hcg) is not a marker of increased trophoblast mitogenic activity. In: Acta Diabetologica Latina. 1997 ; Vol. 176, No. 1 PART II. pp. S158.
@article{b77bb353edda4ab693ab9b90c9528fa5,
title = "Elevation of maternal serum human chorionic gonadotropin (hcg) is not a marker of increased trophoblast mitogenic activity",
abstract = "OBJECTIVE: Second trimester elevation of maternal serum (MS) hCG has been associated with untoward pregnancy outcome, yet its pathogenesis is unknown. We have hypothesized that elevated hCG is due to increased trophoblast proliferation. To test this hypothesis we have measured amniotic fluid (AF) levels of hepatocyte growth factor (HGF), a potent mitogenic and angiogenic factor released by and active on second trimester syncytiotrophoblast. STUDY DESIGN: AF levels of HGF {Quantikine, R&D Systems) in women with elevated MS hCG at the triple screening who underwent second trimester amniocentesis (n=20) were compared with those of women who had normal MS hCG levels at triple screening and underwent amniocentesis for standard genetic indications (n = 40). Included were singleton gestations with no evidence of fetal structural or chromosomal anomalies. Statistical analysis included x2. one-way ANOVA, multivariate analysis and correlation after log-transformation. RESULTS: Mean ±standard deviation maternal age {29±8 vs 36±7 years, p<0.05) and gestational age at sampling f 19±4 weeks vs 17±2 weeks, p<0.05) were different between women with high MS hCG vs those of women with normal or unknown hCG levels. AF HGF levels were not significantly different between the two groups (95,165± 68,825 vs 71,507±56,414, respectively, p=0.62). The lack of significance persisted after correcting for maternal age, gestational age at sampling, and year of sampling. CONCLUSIONS: Elevation of MS hCG is not associated with increased production and release of the mitogen HGF into the AF.",
author = "A. Ghidini and Spong, {C. Y.} and C. Lmtckf and Dildy, {G. A.} and J. Greenhagen and Varner, {M. V.} and M. Ossandon and Pezzulla, {J. C.}",
year = "1997",
month = "12",
day = "1",
language = "English (US)",
volume = "176",
pages = "S158",
journal = "Acta Diabetologica",
issn = "0940-5429",
publisher = "Casa Editrice II Ponte",
number = "1 PART II",

}

TY - JOUR

T1 - Elevation of maternal serum human chorionic gonadotropin (hcg) is not a marker of increased trophoblast mitogenic activity

AU - Ghidini, A.

AU - Spong, C. Y.

AU - Lmtckf, C.

AU - Dildy, G. A.

AU - Greenhagen, J.

AU - Varner, M. V.

AU - Ossandon, M.

AU - Pezzulla, J. C.

PY - 1997/12/1

Y1 - 1997/12/1

N2 - OBJECTIVE: Second trimester elevation of maternal serum (MS) hCG has been associated with untoward pregnancy outcome, yet its pathogenesis is unknown. We have hypothesized that elevated hCG is due to increased trophoblast proliferation. To test this hypothesis we have measured amniotic fluid (AF) levels of hepatocyte growth factor (HGF), a potent mitogenic and angiogenic factor released by and active on second trimester syncytiotrophoblast. STUDY DESIGN: AF levels of HGF {Quantikine, R&D Systems) in women with elevated MS hCG at the triple screening who underwent second trimester amniocentesis (n=20) were compared with those of women who had normal MS hCG levels at triple screening and underwent amniocentesis for standard genetic indications (n = 40). Included were singleton gestations with no evidence of fetal structural or chromosomal anomalies. Statistical analysis included x2. one-way ANOVA, multivariate analysis and correlation after log-transformation. RESULTS: Mean ±standard deviation maternal age {29±8 vs 36±7 years, p<0.05) and gestational age at sampling f 19±4 weeks vs 17±2 weeks, p<0.05) were different between women with high MS hCG vs those of women with normal or unknown hCG levels. AF HGF levels were not significantly different between the two groups (95,165± 68,825 vs 71,507±56,414, respectively, p=0.62). The lack of significance persisted after correcting for maternal age, gestational age at sampling, and year of sampling. CONCLUSIONS: Elevation of MS hCG is not associated with increased production and release of the mitogen HGF into the AF.

AB - OBJECTIVE: Second trimester elevation of maternal serum (MS) hCG has been associated with untoward pregnancy outcome, yet its pathogenesis is unknown. We have hypothesized that elevated hCG is due to increased trophoblast proliferation. To test this hypothesis we have measured amniotic fluid (AF) levels of hepatocyte growth factor (HGF), a potent mitogenic and angiogenic factor released by and active on second trimester syncytiotrophoblast. STUDY DESIGN: AF levels of HGF {Quantikine, R&D Systems) in women with elevated MS hCG at the triple screening who underwent second trimester amniocentesis (n=20) were compared with those of women who had normal MS hCG levels at triple screening and underwent amniocentesis for standard genetic indications (n = 40). Included were singleton gestations with no evidence of fetal structural or chromosomal anomalies. Statistical analysis included x2. one-way ANOVA, multivariate analysis and correlation after log-transformation. RESULTS: Mean ±standard deviation maternal age {29±8 vs 36±7 years, p<0.05) and gestational age at sampling f 19±4 weeks vs 17±2 weeks, p<0.05) were different between women with high MS hCG vs those of women with normal or unknown hCG levels. AF HGF levels were not significantly different between the two groups (95,165± 68,825 vs 71,507±56,414, respectively, p=0.62). The lack of significance persisted after correcting for maternal age, gestational age at sampling, and year of sampling. CONCLUSIONS: Elevation of MS hCG is not associated with increased production and release of the mitogen HGF into the AF.

UR - http://www.scopus.com/inward/record.url?scp=33748598681&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=33748598681&partnerID=8YFLogxK

M3 - Article

AN - SCOPUS:33748598681

VL - 176

SP - S158

JO - Acta Diabetologica

JF - Acta Diabetologica

SN - 0940-5429

IS - 1 PART II

ER -